GEN 0101

Drug Profile

GEN 0101

Alternative Names: GEN0101; HVJ-E; TSD-0014

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GenomIdea
  • Developer GenomIdea; Ishihara Sangyo Kaisha; Osaka University Hospital; TSD Japan
  • Class Antineoplastics; Viral envelope proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Mesothelioma
  • Phase I Prostate cancer

Most Recent Events

  • 22 Aug 2017 Osaka University Hospital completes a phase I trial in Prostate cancer (Recurrent, Second-line therapy or greater) in Japan (Intratumoural) (SC) (UMIN000017092)
  • 12 Apr 2017 GenomIdea initiates enrolment in the GEN0101-JM003 clinical trial for Mesothelioma (Treatment-resistant) (SC) (Intratumoural)
  • 07 Apr 2017 Phase-I/II clinical trials in Mesothelioma (Treatment-resistant) in Japan (SC) before April 2017 (UMIN000026892)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top